PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

PhaseBio Pharmaceuticals, Inc.

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. 

Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
account payables	433K -	430K 0.69%	1.81M 320%	2.92M 61.74%	3.67M 25.78%	12.57M 242.13%
accumulated other comprehensive income loss	-1.55M -	-1.65M 6.20%	-1.78M 8.51%	-1.96M 9.75%
cash and cash equivalents	3.71M -	13.41M 260.86%	61.03M 355.25%	74.03M 21.29%	28.12M 62.01%	41.80M 48.64%
cash and short term investments	3.71M -	13.41M 260.86%	61.03M 355.25%	74.03M 21.29%	28.12M 62.01%	41.80M 48.64%
common stock	1K -	1K 0%	25K 2,400%	29K 16%	29K 0%	48K 65.52%
deferred revenue						1.55M -
deferred revenue non current						7.62M -
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		2.63M -	7.50M 185.71%	12.33M 64.35%	6.77M 45.05%	2.43M 64.09%
long term investments
net debt	-3.71M -	2.08M 155.85%	-53.53M 2,679.81%	-59.32M 10.82%	-15.99M 73.04%	-33.95M 112.30%
net receivables			233K -	1.23M 429.18%
other assets
other current assets	169K -	340K 101.18%	1.36M 301.18%	3.56M 161.36%	12.03M 237.36%	6.98M 41.93%
other current liabilities	411K -	17.16M 4,076.40%	2.77M 83.86%	3.18M 14.76%	5.93M 86.51%	8.35M 40.84%
other liabilities
other non current assets	51K -	51K 0%	43K 15.69%	32K 25.58%	57K 78.13%	57K 0%
other non current liabilities	90.45M -	91.30M 0.93%	22K 99.98%	1.71M 7,677.27%	53.83M 3,045.88%	115.64M 114.83%
othertotal stockholders equity	3.18M -	3.29M 3.42%	112.57M 3,318.52%	224.07M 99.04%	235.49M 5.10%	298.71M 26.85%
preferred stock			63.03M -
property plant equipment net	182K -	302K 65.93%	355K 17.55%	3.64M 925.07%	10.15M 178.95%	11.70M 15.25%
retained earnings	-88.82M -	-99.06M 11.54%	-122.91M 24.07%	-162.16M 31.93%	-260.72M 60.78%	-391.79M 50.27%
short term debt				2.38M -	5.36M 125.19%	5.41M 1.08%
short term investments
tax assets
tax payables
total assets	4.12M -	14.10M 242.46%	63.03M 347.02%	82.49M 30.89%	50.36M 38.96%	60.54M 20.22%
total current assets	3.88M -	13.75M 253.91%	62.63M 355.61%	78.82M 25.86%	40.15M 49.06%	48.78M 21.51%
total current liabilities	844K -	17.59M 1,984.72%	4.58M 73.99%	8.48M 85.25%	14.96M 76.44%	27.88M 86.38%
total debt		15.48M -	7.50M 51.55%	14.70M 96.05%	12.13M 17.52%	7.84M 35.31%
total investments
total liabilities	91.30M -	111.52M 22.14%	12.10M 89.15%	22.52M 86.10%	75.56M 235.58%	153.57M 103.25%
total liabilities and stockholders equity	4.12M -	14.10M 242.46%	63.03M 347.02%	82.49M 30.89%	50.36M 38.96%	60.54M 20.22%
total non current assets	233K -	353K 51.50%	398K 12.75%	3.67M 822.36%	10.21M 178.07%	11.76M 15.16%
total non current liabilities	90.45M -	93.92M 3.83%	7.52M 91.99%	14.04M 86.61%	60.60M 331.71%	125.69M 107.41%
total stockholders equity	-87.18M -	-97.42M 11.74%	50.93M 152.28%	59.98M 17.77%	-25.20M 142.02%	-93.03M 269.15%

COM:PHASEBIO

PhaseBio Pharmaceuticals, Inc.

Last Close

0.07

17/09 20:00

Volume Today

8.56M

Avg: -

Preview